Raymond G. Murphy New Mexico Veterans Affairs Medical Center, Section of Hematology/Oncology, Albuquerque, NM.
Durham Veterans Affairs Medical Center, Division of Hematology and Oncology, Durham, NC.
JCO Oncol Pract. 2021 Jul;17(7):e1012-e1020. doi: 10.1200/OP.20.00703. Epub 2021 Mar 29.
Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non-small-cell lung cancer (NSCLC). Patients with highly actionable gene variants have improved outcomes and reduced toxicities with the use of corresponding targeted agents. We sought to identify barriers to targeted agent use within the Veterans Health Affairs' National Precision Oncology Program (NPOP).
A retrospective evaluation of patients with NSCLC who underwent NGS multigene panels through NPOP between July 2015 and February 2019 was conducted. Patients who were assigned level 1 or 2A evidence for oncogenic gene variants by an artificial intelligence offering (IBM Watson for Genomics [WfG]) and NPOP staff were selected. Antineoplastic drug prescriptions and provider notes were reviewed. Reasons for withholding targeted treatments were categorized.
Of 1,749 patients with NSCLC who successfully underwent NGS gene panel testing, 112 (6.4%) patients were assigned level 1 and/or 2A evidence for available targeted treatments by WfG and NPOP staff. All highly actionable gene variants were within , , , , , , and . Of these, 36 (32.1%) patients were not prescribed targeted agents. The three most common reasons were (1) patient did not carry a diagnosis of metastatic disease (33.3%), (2) treating provider did not comment on the NGS results (25.0%), and (3) provider felt that patient could not tolerate therapy (19.4%). No patients were denied access to level 1 or 2A targeted drugs because of rejection of a nonformulary drug request.
A substantial minority of patients with NSCLC bearing highly actionable gene variants are not prescribed targeted agents. Further provider- and pathologist-directed educational efforts and implementation of health informatics systems to provide real-time decision support for test ordering and interpretation are needed.
下一代测序(NGS)基因面板常用于晚期非小细胞肺癌(NSCLC)患者。具有高度可操作基因变异的患者使用相应的靶向药物可改善预后并降低毒性。我们旨在确定退伍军人健康管理局国家精准肿瘤学计划(NPOP)中靶向药物使用的障碍。
对 2015 年 7 月至 2019 年 2 月期间通过 NPOP 进行 NGS 多基因面板检测的 NSCLC 患者进行回顾性评估。选择经人工智能(IBM Watson for Genomics [WfG])和 NPOP 工作人员分配为 1 级或 2A 级证据的具有致癌基因变异的患者。审查抗肿瘤药物处方和提供者记录。将拒绝靶向治疗的原因进行分类。
在 1749 例成功进行 NGS 基因面板检测的 NSCLC 患者中,有 112 例(6.4%)患者被 WfG 和 NPOP 工作人员分配为具有可用靶向治疗的 1 级和/或 2A 级证据。所有高度可操作的基因变异均在 、 、 、 、 、 和 中。其中,36 例(32.1%)患者未开具靶向药物。最常见的三个原因是:(1)患者未携带转移性疾病的诊断(33.3%);(2)治疗提供者未对 NGS 结果发表意见(25.0%);(3)提供者认为患者无法耐受治疗(19.4%)。没有患者因拒绝非处方药物申请而被拒绝使用 1 级或 2A 级靶向药物。
具有高度可操作基因变异的 NSCLC 患者中,有相当一部分未开具靶向药物。需要进一步开展针对提供者和病理学家的教育工作,并实施卫生信息系统,为测试订单和解释提供实时决策支持。